Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of DR10624 in severe hypertriglyceridemia
CTR20262355Phase 3Active
- Sponsor
- Zhejiang Daer Biotechnology
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia comparing DR10624 with Placebo (2 arms). Primary endpoint: Percent change from baseline in fasting triglycerides versus placebo. Started Aug 2026; status: active.
02
Drugs
DR10624
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on CTR20262355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262355.